ALAUNOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) -…

Item 1.01 Entry into a Material Definitive Agreement.

On June 24, 2022, Alaunos Therapeutics, Inc. (the "Company") entered intoAmendment #4 (the "Fourth Amendment") to a Cooperative Research and DevelopmentAgreement, dated January 9, 2017, by and among the National Cancer Institute,the Company and Precigen, Inc., as amended (the "CRADA"). The Fourth Amendment,among other things, extends the term of the CRADA until January 9, 2025.

The foregoing summary of the Fourth Amendment does not purport to be completeand is qualified in its entirety by reference to the full text of the FourthAmendment, a copy of which, subject to any applicable confidential treatment,will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q forthe period ended June 30, 2022.

Item 7.01 Regulation FD Disclosure.

On June 27, 2022, the Company issued a press release announcing the entry intothe Fourth Amendment. A copy of the press release is furnished as Exhibit 99.1to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, is being"furnished" and shall not be deemed "filed" for purposes of Section 18 of theSecurities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwisesubject to the liability of that Section or Sections 11 and 12(a)(2) of theSecurities Act of 1933, as amended (the "Securities Act"). The informationcontained in this Item 7.01, including Exhibit 99.1, shall not be incorporatedby reference into any registration statement or other document pursuant to theSecurities Act or into any filing or other document pursuant to the ExchangeAct, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Excerpt from:
ALAUNOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) -...